No Data
No Data
Oncocyte Prices $29 Million Stock Offerings
Express News | OncoCyte Corp: Proceeds Expected to Fund Transplant Assay Through FDA Ivd Clearance and Commercial Launch
Express News | OncoCyte Prices $29.1 Million Equity Offering
Wells Fargo Maintains Bio-Rad Laboratories(BIO.US) With Hold Rating, Maintains Target Price $360
Wells Fargo Sticks to Their Hold Rating for Bio-Rad Laboratories (BIO)
Bio-Rad Laboratories (BIO.US) will release its Earnings Reports after the market closes on February 13.
$Bio-Rad Laboratories (BIO.US)$ will release its Earnings Reports after the market closes on February 13. Investors should pay attention. How were the previous results? $Bio-Rad Laboratories (BIO.US)$ had a revenue of $0.65 billion and a Net income of $0.653 billion in Q3 2024, with an EPS of $23.34. In Q4 2023, the revenue was $0.681 billion, Net income was $0.35 billion, and the EPS was $12.14. The accounting standards used for the above data are US_GAAP. Futubull reminds: 1. The accounting year division for Hong Kong and U.S. listed companies does not have
Unlock the Full List